The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease

References

• EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer [Internet]. European Association of Urology. 2022.
   Google Scholar
• Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on Prostate Cancer, Part 1: Early Detection, Diagnostics, Staging, Patient Support and Primary Management of Non-metastatic Disease. Scand J Urol. 2022.
   Web of Science ®Google Scholar
• Shen MJ, Nelson CJ, Peters E, et al. Decision-making processes among Prostate Cancer Survivors with Rising PSA Levels: Results from a Qualitative Analysis. Med Decis Making. 2015;35(4):477–486.
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Hayoz S, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK), et al. Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09/10 randomized phase 3 trial. Eur Urol. 2021;80(3):306–315.
   PubMed Web of Science ®Google Scholar
• Dess RT, Sun Y, Jackson WC, et al. Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer. JAMA Oncol. 2020;6(5):735–743.
   PubMed Web of Science ®Google Scholar
• Carrie C, Magne N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740–1749.
   PubMed Web of Science ®Google Scholar
• Valle LF, Lehrer EJ, Markovic D, et al. A systematic review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2021;80(3):280–292.
   PubMed Web of Science ®Google Scholar
• Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–1216.
   PubMed Web of Science ®Google Scholar
• Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447–460.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;1389(10024):1163–1177.
   Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121–131.
   PubMed Web of Science ®Google Scholar
• Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN Study. J Clin Oncol. 2021;39(20):2294–2303. 10
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Shore ND, Szmulewitz RZ, et al. Efficacy of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread: ARCHES post hoc analyses. J Urol. 2021;205(5):1361–1371.
   PubMed Web of Science ®Google Scholar
• Thomsen FB, Brasso K, Christensen IJ, Scandinavian Prostate Cancer Group, et al. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study. Eur J Cancer. 2015;51(10):1283–1292.
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33(5):447–456.
   PubMed Web of Science ®Google Scholar
• Beckmann K, Garmo H, Adolfsson J, et al. Androgen deprivation therapies and changes in comorbidity: a comparison of gonadotropin-releasing hormone agonists and antiandrogen monotherapy as primary therapy in men with high-risk prostate cancer. Eur Urol. 2019;75(4):676–683.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022;399(10336):1695–1707.
   PubMed Web of Science ®Google Scholar
• Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132–1142. Epub 20220217.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–1418.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Fizazi K, Saad F, PROSPER Investigators, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382(23):2197–2206.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, ARAMIS Investigators, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383(11):1040–1049.
   PubMed Web of Science ®Google Scholar
• Maughan BL, Antonarakis ES. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother. 2015;16(10):1521–1537.
   PubMed Web of Science ®Google Scholar
• Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):408–419.
   PubMed Web of Science ®Google Scholar
• Agency EM. EMA restricts use of prostate cancer medicine Xofigo https://www.ema.europa.eu/en/news/ema-restricts-use-prostate-cancer-medicine-xofigo2018. [2022-02-14].
   Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m(2)) and the currently approved dose (25 mg/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol. 2017;35(28):3198–3206.
   PubMed Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102.
   PubMed Web of Science ®Google Scholar
• Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–1103.
   PubMed Web of Science ®Google Scholar
• Sella A, Sternberg CN, Skoneczna I, et al. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU Int. 2008;102(11):1607–1609.
   PubMed Web of Science ®Google Scholar
• Mikah P, Krabbe LM, Eminaga O, et al. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC Cancer. 2016;16(1):214.
   PubMedGoogle Scholar
• Thorstenson A, Bratt O, Akre O, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer. 2012;48(11):1672–1681.
   PubMed Web of Science ®Google Scholar
• Wu CC, Chen PY, Wang SW, et al. Risk of fracture during androgen deprivation therapy among patients with prostate cancer: a systematic review and meta-analysis of cohort studies. Front Pharmacol. 2021;12:652979.
   PubMed Web of Science ®Google Scholar
• Li G, Thabane L, Papaioannou A, et al. An overview of osteoporosis and frailty in the elderly. BMC Musculoskelet Disord. 2017;18(1):46.
   PubMedGoogle Scholar
• Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98(5):962–969.
   PubMed Web of Science ®Google Scholar
• Borggrefe J, Giravent S, Campbell G, et al. Association of osteolytic lesions, bone mineral loss and trabecular sclerosis with prevalent vertebral fractures in patients with multiple myeloma. Eur J Radiol. 2015;84(11):2269–2274.
   PubMed Web of Science ®Google Scholar
• Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017;317(1):48–58.
   PubMed Web of Science ®Google Scholar